Skip to main content

Table 4 MarketScan Database: Lung NET Prevalence, Cases per Million per Yeara

From: Incidence and prevalence of neuroendocrine tumors of the lung: analysis of a US commercial insurance claims database

 

No. Of Cases Per Million Per Year (Numerator/Denominator)

2009

2010

2011

2012

2013

2014

Gender

Age

                  

 Female

18–24

1.7

(2

/1,200,214)

1.7

(2

/1,179,801)

0.7

(1

/1,535,683)

3.0

(5

/1,668,409)

3.6

(5

/1,404,034)

0.7

(1

/1,342,845)

25–34

4.9

(10

/2,032,535)

8.2

(16

/1,962,108)

5.8

(12

/2,052,889)

10.5

(22

/2,089,096)

9.8

(16

/1,640,542)

8.3

(13

/1,562,298)

35–44

7.6

(20

/2,616,976)

9.9

(25

/2,533,283)

12.9

(34

/2,643,239)

14.7

(39

/2,660,474)

18.8

(40

/2,123,456)

21.0

(42

/1,996,743)

45–54

18.1

(56

/3,090,478)

24.7

(75

/3,031,223)

31.0

(99

/3,190,617)

36.8

(118

/3,204,967)

40.3

(102

/2,529,219)

42.4

(99

/2,336,993)

55–64

52.8

(124

/2,349,482)

59.7

(144

/2,411,232)

75.1

(197

/2,624,303)

85.9

(231

/2,688,474)

95.2

(209

/2,194,982)

102.3

(210

/2,053,379)

All Female

18.8

(212

/11,289,685)

23.6

(262

/11,117,647)

28.5

(343

/12,046,731)

33.7

(415

/12,311,420)

37.6

(372

/9,892,233)

39.3

(365

/9,292,258)

 Male

18–24

5.2

(6

/1,147,214)

3.5

(4

/1,129,804)

2.6

(4

/1,549,206)

2.3

(4

/1,705,487)

1.4

(2

/1,431,673)

0.0

(0

/1,365,613)

25–34

2.3

(4

/1,760,823)

4.8

(8

/1,669,422)

3.9

(7

/1,788,710)

4.9

(9

/1,850,139)

4.2

(6

/1,436,317)

5.8

(8

/1,388,742)

35–44

7.2

(17

/2,359,613)

7.1

(16

/2,250,466)

11.3

(27

/2,381,647)

9.2

(22

/2,403,534)

8.9

(17

/1,900,182)

12.3

(22

/1,791,028)

45–54

10.3

(28

/2,731,422)

15.9

(42

/2,636,290)

16.7

(47

/2,817,734)

21.1

(60

/2,841,640)

18.4

(41

/2,223,287)

24.2

(50

/2,066,977)

55–64

33.7

(71

/2,104,573)

30.8

(65

/2,107,551)

38.3

(88

/2,296,348)

45.7

(107

/2,342,101)

42.7

(81

/1,897,684)

52.1

(93

/1,783,325)

All Male

12.5

(126

/10,103,645)

13.8

(135

/9,793,533)

16.0

(173

/10,833,645)

18.1

(202

/11,142,901)

16.5

(147

/8,889,143)

20.6

(173

/8,395,685)

 All Gender

18–24

3.4

(8

/2,347,428)

2.6

(6

/2,309,605)

1.6

(5

/3,084,889)

2.7

(9

/3,373,896)

2.5

(7

/2,835,707)

0.4

(1

/2,708,458)

25–34

3.7

(14

/3,793,358)

6.6

(24

/3,631,530)

4.9

(19

/3,841,599)

7.9

(31

/3,939,235)

7.2

(22

/3,076,859)

7.1

(21

/2,951,040)

35–44

7.4

(37

/4,976,589)

8.6

(41

/4,783,749)

12.1

(61

/5,024,886)

12.0

(61

/5,064,008)

14.2

(57

/4,023,638)

16.9

(64

/3,787,771)

45–54

14.4

(84

/5,821,900)

20.6

(117

/5,667,513)

24.3

(146

/6,008,351)

29.4

(178

/6,046,607)

30.1

(143

/4,752,506)

33.8

(149

/4,403,970)

55–64

43.8

(195

/4,454,055)

46.3

(209

/4,518,783)

57.9

(285

/4,920,651)

67.2

(338

/5,030,575)

70.9

(290

/4,092,666)

79.0

(303

/3,836,704)

All Patients

15.8

(338

/21,393,330)

19.0

(397

/20,911,180)

22.6

(516

/22,880,376)

26.3

(617

/23,454,321)

27.6

(519

/18,781,376)

30.4

(538

/17,687,943)

 

Adjusted Rate (No. Of Cases Per Million Per Year)b

All Femalec

19.2

23.5

28.6

34.0

37.9

39.8

All Maled

12.6

13.5

15.9

18.3

16.7

20.9

All Patientse

16.0

18.7

22.5

26.4

27.6

30.7

  1. a Cases of adults with ≥1 inpatient or ≥ 2 outpatient claims for Lung NET in listed year and continuous enrollment in year listed ÷ number of members with continuous enrollment in same period
  2. bAPC (95% CI; P value): female 16.2% (11.4–21.1; <.001); male 9.9% (4.7–15.3; 0.006); all patients: 14.0% (10.2–17.9; <.001)
  3. cAdjusted based on distribution of age among males from both databases in 2014
  4. dAdjusted based on distribution of age among females from both databases in 2014
  5. eAdjusted based on combined distribution of age among males from both databases in 2014
Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us